The clinical effect of Sitagliptin Phosphate Tablets combined with shenmai on type 2 diabetes
10.3760/cma.j.issn.1008-6706.2012.22.013
- VernacularTitle:西格列汀联合参麦注射液治疗2型糖尿病的疗效观察
- Author:
Kaiyuan LIU
;
Fangfang ZHANG
- Publication Type:Journal Article
- Keywords:
Sitagliptin Phosphate Tablets;
Shenmai;
Diabetes,type 2
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;(22):3387-3389
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of Sitagliptin Phosphate Tablets combined with shenmai on type 2 diabetes.Methods Sixty diabetes patients were divided into two groups randomly:treatment group were received Sitagliptin Phosphate Tablets and shenmai;the control group were given acarbose.14 weeks later,the indications FBG,2HBG,HbA1 C,TC,TG,LDL-C,HDL-C,hypoglycemia happen rate,BMI,blood rheology,transcranial Doppler ultrasound(TCD)were tested to see if there is any change.Results After treatment,two groups of FBG,2hBG,HbA1 C,TC,TG,LDL-C,HDL-C levels compared with those before treatment were statistically significant(P＜0.05 or P＜0.01),but the treatment group on lipid control more than those in the control group;treatment group therapy in reducing the risk of hypoglycaemia and weight gain than the control group(P＜0.05);the whole blood viscosity,plasma viscosity,low viscosity and hematocrit of treatment group were significantly lower(P＜0.05),while the control group showed no significant change;the abnormal rate of treatment group was 52.6％,significantly better than the control group 86.5％(P＜0.05).Conclusion The effect of Sitagliptin Phosphate Tablets combined with shenmai on type 2 diabetes was significant,compared with the traditional antidiabetic drugs,the combination is effective hypoglycemic control fat and less adverse reactions.
